The ACT-Accelerator is a global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
From research to rollout, the ACT-Accelerator remains the world’s only end-to-end solution to end the COVID-19 pandemic.
The partnership is structured around the three pillars of Diagnostics, Therapeutics and Vaccines (COVAX), with a cross-cutting Health Systems and Response Connector (HSRC) and Access and Allocation workstream. Find out more on the Areas of Work page.
The co-convening agencies of the ACT-Accelerator are: CEPI, FIND, Gavi, The Global Fund, UNICEF, Unitaid, Wellcome, WHO, the World Bank and The Bill & Melinda Gates Foundation.
Leaders from each of the agencies make up the 'Principals Group', which addresses cross-cutting strategy and delivery considerations, with representatives from industry, CSOs, international financial institutions, and the Facilitation Council invited to participate in meetings.
Agencies & Principals Group
There are two WHO Special Envoys for the ACT-Accelerator.
Dr. Ayoade Alakija, Co-Chair of the Africa Union Africa Vaccine Delivery Alliance for COVID-19 (AVDA)
Carl Bildt, former Prime Minister of Sweden and co-chair, European Council on Foreign Relations
The Special Envoys help lead the ACT-Accelerator’s collective advocacy, support the pillar and HSRC leaders, consult widely on the work of the ACT-Accelerator; advise the Director-General, ACT-Accelerator Principals and stakeholders on emerging issues; and represent the ACT-Accelerator in key national and international fora.
ACT-A Special Envoys
Civil Society Engagement
The Civil Society Platform (co-led by WACI Health, Global Fund Advocates Network (GFAN) and STOPAIDS) supports community and civil society representatives in the ACT-Accelerator. The platform advocates to ensure every aspect of the ACT-Accelerator has reserved space for communities and civil society to bring their expertise, experience and voices to the COVID-19 response.
The ACT-Accelerator engages with key
industry groups, such as the International Federation of Pharmaceutical Manufacturers & Associations (IPFMA), International Generic and Biosimilar Medicines Association (IGBA), and Developing Countries Vaccine Manufacturers Network (DCVMN).